MicroRNA-based logic gates and uses thereof
The present disclosure, at least in part, relates to a miRNA based logic gate that comprises an engineered RNA carrier that comprises an nuclear export signal, a target site for a first miRNA and a pre-miRNA sequence for a second miRNA. Also provided by the disclosure are recombinant viruses (e.g., recombinant adeno-associated viruses (rAAV)) for delivery of the miRNA based logic gates.
1. An miRNA based logic gate comprising an engineered RNA carrier, wherein the engineered RNA carrier comprises:
(i) a small nuclear RNA (snRNA) nuclear export sequence and an snRNA nuclear import sequence;
(ii) a target site for a first microRNA (miRNA); and
(iii) one or more pre-miRNA sequences of a second microRNA (miRNA).
2. The miRNA based logic gate of claim 1 , wherein the miRNA based logic gate is a NOT gate.
3. An miRNA based logic gate, wherein the miRNA based logic gate is:
a) a NOR gate comprising the miRNA based NOT gate of claim 2 and a target site for a third miRNA; or b) a NAND gate comprising two miRNA based NOT gates of claim 2 .
4. An miRNA based logic gate, wherein the miRNA logic gate is a miRNA-based flip flop, which comprises two miRNA based NOR gates or two miRNA based NAND gates of claim 3 .
5. The miRNA based logic gate of claim 1 , wherein the snRNA nuclear export sequence is derived from pre-U1 snRNA, pre-U2 snRNA, pre-U3 snRNA, pre-U4 snRNA, pre-U5 snRNA, pre-U6 snRNA, pre-U7 snRNA, pre-U4atac snRNA, pre-U11 snRNA, or pre-U12 snRNA
wherein the snRNA nuclear import sequence is derived from pre-U1 snRNA, pre-U2 snRNA, pre-U3 snRNA, pre-U4 snRNA, pre-U5 snRNA, pre-U6 snRNA, pre-U7 snRNA, pre-U4atac snRNA, pre-U11 snRNA, or pre-U12 snRNA.
6. The miRNA based logic gate of claim 1 , wherein the engineered RNA carrier further comprises
a) a sequence that binds to the survival of motor neuron complex (SMN complex); and/or
b) a 3′ cap.
7. The miRNA based logic gate of claim 1 , wherein the snRNA nuclear import sequence and the snRNA nuclear export sequence are derived from the same snRNA.
8. The miRNA based logic gate of claim 1 , wherein the snRNA nuclear import sequence is not a pre-U6 snRNA nuclear import sequence, wherein the snRNA nuclear export sequence is not a pre-U6 snRNA nuclear export sequence.
9. An engineered nucleic acid comprising a promoter operably linked to a nucleotide sequence encoding the miRNA based logic gate of claim 1 .
10. A recombinant virus, optionally a recombinant AAV (rAAV), comprising: a viral capsid containing a promoter operably linked to a nucleotide sequence encoding the miRNA based logic gate of claim 1 .
11. An isolated cell comprising the miRNA based logic gate of claim 1 , optionally wherein the cell is:
a) a prokaryotic cell, optionally a bacterial cell;
b) a eukaryotic cell, optionally a fungal cell, plant cell, insect cell, or mammalian cell, optionally a human cell;
c) a diseased cell; and/or
d) from a specific tissue.
12. The isolated cell of claim 11 , wherein the cell expresses the first miRNA, and does not express the second miRNA.
13. The isolated cell of claim 11 , wherein the cell does not express the first microRNA, and expresses the second miRNA.
14. The isolated cell of claim 11 , wherein the cell expresses both the first miRNA and the second miRNA, and downregulation of the first miRNA leads to the upregulation of the second miRNA.
15. The isolated cell of claim 11 , wherein the cell expresses both the first and the second miRNA, and upregulation of the first miRNA leads to the downregulation of the second miRNA.
16. A pharmaceutical composition, comprising the miRNA based logic gate of claim 1 and a pharmaceutically acceptable carrier.
17. A method comprising delivering the miRNA based logic gate of claim 1 to a subject, optionally a human or non-human mammal, in need thereof.
18. A method for delivering a miRNA to a specific cell type in a subject, optionally a human or non-human mammal, in need thereof, comprising administering to the subject an effective amount of the miRNA based logic gate of claim 1 .
19. A method for treating a disease in a subject, optionally a human or non-human mammal, in need thereof, comprising administering to the subject an effective amount of the miRNA based logic gate of claim 1 .
20. The method of claim 19 , wherein the subject has or is at risk of having Alpha-1 antitrypsin deficiency, Hypercholesterolemia, Hepatitis B infection, Liver adenoma due to HIV infection, Hepatitis C virus infection, Ornithine transcarbamylase deficiency, Hepatocellular carcinoma, Amyotrophic lateral sclerosis, Spinocerebellar ataxia type 1, Huntington's disease, Parkinson disease, Spinal and Bulbar muscular atrophy, Pyruvate dehydrogenase deficiency, Hyperplasia, obesity, FSHD, Nerve Injury-induced Neuropathic Pain, Age-related macular degeneration, Retinitis pigmentosa, heart failure, cardiomyopathy, cold-induced cardiovascular dysfunction, Asthma, Duchenne muscular dystrophy, or prostate cancer.